212 related articles for article (PubMed ID: 23844053)
1. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
Ferguson BD; Liu R; Rolle CE; Tan YH; Krasnoperov V; Kanteti R; Tretiakova MS; Cervantes GM; Hasina R; Hseu RD; Iafrate AJ; Karrison T; Ferguson MK; Husain AN; Faoro L; Vokes EE; Gill PS; Salgia R
PLoS One; 2013; 8(7):e67668. PubMed ID: 23844053
[TBL] [Abstract][Full Text] [Related]
2. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
Ferguson BD; Carol Tan YH; Kanteti RS; Liu R; Gayed MJ; Vokes EE; Ferguson MK; John Iafrate A; Gill PS; Salgia R
Sci Rep; 2015 Jun; 5():10641. PubMed ID: 26073592
[TBL] [Abstract][Full Text] [Related]
3. EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Becerikli M; Merwart B; Lam MC; Suppelna P; Rittig A; Mirmohammedsadegh A; Stricker I; Theiss C; Singer BB; Jacobsen F; Steinstraesser L
Int J Cancer; 2015 Apr; 136(8):1781-91. PubMed ID: 25274141
[TBL] [Abstract][Full Text] [Related]
4. EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.
Xuqing W; Lei C; Zhengfa M; Shengchun D; Xin F; Jianguo Q; Jianxin Z
Tumour Biol; 2012 Oct; 33(5):1419-27. PubMed ID: 22528941
[TBL] [Abstract][Full Text] [Related]
5. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Zhu M; Shi X; Gong Z; Su Q; Yu R; Wang B; Yang T; Dai B; Zhan Y; Zhang D; Zhang Y
Pharmacol Res; 2020 Aug; 158():104868. PubMed ID: 32407961
[TBL] [Abstract][Full Text] [Related]
6. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
7. Targeting receptor tyrosine kinase EphB4 in cancer therapy.
Chen Y; Zhang H; Zhang Y
Semin Cancer Biol; 2019 Jun; 56():37-46. PubMed ID: 28993206
[TBL] [Abstract][Full Text] [Related]
8. EphB4: A promising target for upper aerodigestive malignancies.
Salgia R; Kulkarni P; Gill PS
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):128-137. PubMed ID: 29369779
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of EphB4 in mesothelioma and its biological significance.
Xia G; Kumar SR; Masood R; Koss M; Templeman C; Quinn D; Zhu S; Reddy R; Krasnoperov V; Gill PS
Clin Cancer Res; 2005 Jun; 11(12):4305-15. PubMed ID: 15958611
[TBL] [Abstract][Full Text] [Related]
10. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
[TBL] [Abstract][Full Text] [Related]
11. EphB4 is overexpressed in gliomas and promotes the growth of glioma cells.
Chen T; Liu X; Yi S; Zhang J; Ge J; Liu Z
Tumour Biol; 2013 Feb; 34(1):379-85. PubMed ID: 23138393
[TBL] [Abstract][Full Text] [Related]
12. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Li X; Choi WW; Yan R; Yu H; Krasnoperov V; Kumar SR; Schuckman A; Klumpp DJ; Pan CX; Quinn D; Gill IS; Gill PS; Liu R
PLoS One; 2014; 9(8):e105326. PubMed ID: 25148033
[TBL] [Abstract][Full Text] [Related]
13. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Masood R; Kumar SR; Sinha UK; Crowe DL; Krasnoperov V; Reddy RK; Zozulya S; Singh J; Xia G; Broek D; Schönthal AH; Gill PS
Int J Cancer; 2006 Sep; 119(6):1236-48. PubMed ID: 16615113
[TBL] [Abstract][Full Text] [Related]
14. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Kumar SR; Singh J; Xia G; Krasnoperov V; Hassanieh L; Ley EJ; Scehnet J; Kumar NG; Hawes D; Press MF; Weaver FA; Gill PS
Am J Pathol; 2006 Jul; 169(1):279-93. PubMed ID: 16816380
[TBL] [Abstract][Full Text] [Related]
15. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Ferguson BD; Tretiakova MS; Lingen MW; Gill PS; Salgia R
Growth Factors; 2014 Dec; 32(6):202-6. PubMed ID: 25391996
[TBL] [Abstract][Full Text] [Related]
16. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
Martiny-Baron G; Holzer P; Billy E; Schnell C; Brueggen J; Ferretti M; Schmiedeberg N; Wood JM; Furet P; Imbach P
Angiogenesis; 2010 Sep; 13(3):259-67. PubMed ID: 20803239
[TBL] [Abstract][Full Text] [Related]
17. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.
Spannuth WA; Mangala LS; Stone RL; Carroll AR; Nishimura M; Shahzad MM; Lee SJ; Moreno-Smith M; Nick AM; Liu R; Jennings NB; Lin YG; Merritt WM; Coleman RL; Vivas-Mejia PE; Zhou Y; Krasnoperov V; Lopez-Berestein G; Gill PS; Sood AK
Mol Cancer Ther; 2010 Aug; 9(8):2377-88. PubMed ID: 20682653
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.
Bhatia S; Sharma J; Bukkapatnam S; Oweida A; Lennon S; Phan A; Milner D; Uyanga N; Jimeno A; Raben D; Somerset H; Heasley L; Karam SD
Clin Cancer Res; 2018 Sep; 24(18):4539-4550. PubMed ID: 29848571
[No Abstract] [Full Text] [Related]
19. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
Kumar SR; Masood R; Spannuth WA; Singh J; Scehnet J; Kleiber G; Jennings N; Deavers M; Krasnoperov V; Dubeau L; Weaver FA; Sood AK; Gill PS
Br J Cancer; 2007 Apr; 96(7):1083-91. PubMed ID: 17353927
[TBL] [Abstract][Full Text] [Related]
20. EphB4 expression and biological significance in prostate cancer.
Xia G; Kumar SR; Masood R; Zhu S; Reddy R; Krasnoperov V; Quinn DI; Henshall SM; Sutherland RL; Pinski JK; Daneshmand S; Buscarini M; Stein JP; Zhong C; Broek D; Roy-Burman P; Gill PS
Cancer Res; 2005 Jun; 65(11):4623-32. PubMed ID: 15930280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
